Overview of Dr. Osman
Dr. Keren Osman is a hematologist in New York, NY and is affiliated with The Mount Sinai Hospital. She received her medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 21 years. She is one of 52 doctors at The Mount Sinai Hospital who specialize in Hematology. She has more than 30 publications and over 500 citings.
Office
10 E 102nd St
New York, NY 10029Fax+1 212-731-5210
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1996 - 1999- Icahn School of Medicine at Mount SinaiClass of 1996
Certifications & Licensure
NY State Medical License 1997 - 2026
Clinical Trials
- Host Dendritic Cells in Allograft Patients Start of enrollment: 2009 Aug 01
- Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
- Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis Start of enrollment: 2017 Jun 12
Publications & Presentations
PubMed
- 3 citationsPhase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.David G Coffey, Keren Osman, Adolfo Aleman, Selma Bekri, Simone Kats
Journal for Immunotherapy of Cancer. 2024-04-12 - 2 citationsCAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease.Uroosa Ibrahim, Claude Bassil, Julio C Chavez, Farhad Khimani, Michael D Jain
Clinical Lymphoma, Myeloma & Leukemia. 2023-10-01 - CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma.Tyler D'Ovidio, Kathryn Ciccolini, Matko Kalac, Keren Osman, Amir Steinberg
Cureus. 2023-09-01
Abstracts/Posters
- A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...Keren Osman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...Keren Osman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
The Covid Drug Wars That Pitted Doctors vs. DoctorAugust 5th, 2020
Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 PatientsApril 9th, 2020
Regimen Deemed ‘Safe and Feasible’ in MMFebruary 23rd, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
